{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:21Z","timestamp":1791521361599,"version":"4.3.4"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>We describe the safety and early immune response following accidental administration of the live measles\u2013mumps\u2013rubella vaccine in a child receiving baricitinib. No vaccine-related adverse events occurred. The patient demonstrated a satisfactory antibody response to all 3 antigens, which persisted at 6-month follow-up while Janus kinase inhibitor therapy was continued.<\/jats:p>","DOI":"10.1097\/inf.0000000000005274","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:00:42Z","timestamp":1781582442000},"page":"1013-1015","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Early Immune Dynamics Following First Dose of the MMR Vaccine in a Toddler Treated With a JAK Inhibitor"],"prefix":"10.1097","volume":"45","author":[{"given":"Despoina","family":"Maritsi","sequence":"first","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u201cP. & A. Kyriakou\u201d Children\u2019s Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3667-5508","authenticated-orcid":false,"given":"Ariadni","family":"Neofytou","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, \u201cP. & A. Kyriakou\u201d Children\u2019s Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papadimitriou","sequence":"additional","affiliation":[{"name":"Department of Serology, \u201cP. & A. Kyriakou\u201d Children\u2019s Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Marmarinos","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Biochemistry & Molecular Diagnostics, Second Department of Pediatrics, Medical School, National and Kapodistrian University, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.revmed.2025.06.003","article-title":"Safety profile of JAK inhibitors in inflammatory or autoimmune diseases.","volume":"46","author":"Moreau","year":"2025","journal-title":"Rev Med Interne"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system.","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-023-00817-8","article-title":"Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, and AGS).","volume":"21","author":"Kanazawa","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11926-018-0792-7","article-title":"JAK inhibitors in rheumatology: implications for paediatric syndromes?","volume":"20","author":"Kerrigan","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"otae 006","DOI":"10.1093\/crocol\/otae006","article-title":"Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding.","volume":"6","author":"Ernest-Suarez","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-019-1883-1","article-title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.","volume":"21","author":"Winthrop","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.3390\/ijms24086967","article-title":"Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study.","volume":"24","author":"Venerito","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Suppl 136","key":"R9-20261009","first-page":"10","article-title":"First report on the safety of the influenza vaccine in patients with paediatric inflammatory rheumatic diseases on JAK inhibitors.","volume":"43","author":"Maritsi","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021.","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","article-title":"Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection.","volume":"38","author":"Uziel","year":"2020","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:02:34Z","timestamp":1791518554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005274","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"2026-04-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}